Quick Answer
Vivos Therapeutics, Inc. reported Total Assets of $15.28 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +42.4% in Total Assets from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $21.95 million | Q2 2021: $46.16 million | Q3 2021: $41.02 million | Q1 2022: $29.56 million | Q2 2022: $24.38 million | Q3 2022: $18.40 million | Q1 2023: $17.10 million | Q2 2023: $13.75 million | Q3 2023: $10.32 million | Q1 2024: $11.80 million | Q2 2024: $15.84 million | Q3 2024: $15.35 million | Q4 2024: $15.28 million | Q1 2025: $11.28 million | Q2 2025: $26.03 million | Q3 2025: $25.64 million.
- Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Total Assets has grown by 102.4%.
- Historical annual values: Fiscal year 2024: $15.28 million | Fiscal year 2023: $10.73 million | Fiscal year 2022: $13.72 million | Fiscal year 2021: $33.69 million | Fiscal year 2020: $25.33 million | Fiscal year 2019: $7.55 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: